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RESUMO 
 
Na infecção pelo HIV, as células dendríticas (CDs) podem desempenhar 
vários papéis, incluindo a provável captação inicial do HIV, transporte para 
os linfonodos, e posterior transferência para células T, desempenhando um 
importante papel no sistema imune. As manifestações orais observadas em 
pacientes infectados pelo HIV, incluindo aquelas associadas ao HSV-1 
podem estar diretamente relacionadas à injúria das CDs. A proposta deste 
estudo foi identificar e quantificar as CDs intersticiais na língua de pacientes 
autopsiados com AIDS e portadores de infecção herpética lingual (n=10), 
pacientes com AIDS e sem lesões linguais (n=10) e pacientes sem AIDS e 
sem lesões linguais (n=10) por meio de reações imunoistoquímicas. Além 
disso, investigamos a população de CDs nos linfonodos e tonsilas palatinas 
de pacientes com AIDS (n=32) e sem AIDS (n=21). Nos tecidos linguais, 
foram utilizados os anticorpos contra CD1a e CD83 para identificação das 
CDs e o anticorpo contra HSV-1 para detecção do vírus da herpes simples 
tipo 1. Nos linfonodos e tonsilas palatinas foram utilizados além dos 
anticorpos contra CD1a e CD83, o anticorpo contra fator XIIIa. Para a 
quantificação das CDs nos tecidos linguais foi utilizado análise 
histomorfométrica convencional e nos tecidos linfóides foi aplicado o método 
analítico Positive Pixel Count (software Image Scope). Os resultados 
mostraram uma intensa depleção na população de CDs em tecidos linguais 
e linfóides de pacientes com AIDS e a infecção lingual pelo HSV-1 não 
potencializou a redução de CDs.   
 
Palavras-chave: AIDS; células dendríticas; língua; linfonodos; tonsilas; vírus 
herpes simplex. 
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ABSTRACT   
 
During HIV infection, dendritic cells (DCs) may play several roles, including 
the probable initial uptake of HIV, transport to the lymph nodes, and 
subsequent transfer to T cells. Oral opportunistic infections observed in HIV-
infected patients, including those associated with HSV-1 may be directly 
related to injury of DCs. The purpose of this study was to identify and 
quantify the interstitial DCs in the tongue of autopsied patients with AIDS and 
lingual herpes (n = 10), AIDS patients with normal tongues (n = 10) and non-
AIDS patients with normal tongues (n = 10) by immunohistochemistry. 
Furthermore, we investigated the DCs population in lymph nodes and 
palatine tonsils of AIDS patients (n = 32) and non-AIDS patients (n = 21). 
CD1a and CD83 antibodies were carried out to identify DCs in lingual tissues 
and HSV-1 antibody for detection of herpes simplex virus type 1. In lymphoid 
tissues, CD1a, CD83 and factor XIIIa antibodies were carried out to identify 
DCs. Interstitial DCs were measured by conventional histomorphometry 
whereas the lymphoid DCs were measured by Positive Pixel Count Algorithm 
method using ImageScope software. The results showed a decreased 
population of DCs in lingual and lymphoid tissues of AIDS patients 
independently of the presence of concomitant infection by HSV-1.  
 
Key words: AIDS; dendritic cells; tongue; lymph nodes; tonsils; herpes 
simplex virus. 
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INTRODUÇÃO 
  
As células dendríticas (CDs) constituem uma família de células 
apresentadoras de antígenos (APCs) oriundas de progenitores hematopoiéticos da 
medula óssea e com extraordinária capacidade para interagir com os linfócitos T e 
B modulando as suas respostas (Steinman, 2012).  
As CDs apresentam núcleo ovóide ou denteado com cromatina frouxa e um 
citoplasma abundante, exibindo mitocôndrias proeminentes, múltiplas organelas 
citoplasmáticas, como vesículas e túbulos e, usualmente, poucos lisossomos, 
embora estes últimos sejam encontrados em maior número nas CDs presentes no 
tecido conjuntivo de órgãos não linfóides (Hart, 1997; Banchereau & Steinman, 
1998).  
A heterogeneidade das CDs resulta da existência de linhagens celulares 
distintas e diferenças nos estágios de maturação (Shortman & Naik, 2007). 
Mclellan & Kämpgen (2000) afirmaram que as células dendríticas derivam de 
precursores mielóides e linfóides. Em humanos, o desenvolvimento de CDs via 
linfóide é controverso. As CDs mielóides e linfóides diferem em fenótipo, 
localização e função (Steinman et al., 1997). Os subtipos de CDs que estão 
presentes em humanos e camundongos incluem as células dendríticas 
plasmocitóides (CDp), produtoras de interferon tipo-1, e as células dendríticas 
convencionais ou clássicas (CDc), especializadas em processamento e 
apresentação antigênica. Enquanto as CDp completam o desenvolvimento na 
medula óssea, a maioria das CDc completam o desenvolvimento em tecidos 
periféricos e linfóides (Liu & Nussenzweig, 2010). Citocinas adicionais e 
reguladores transcricionais são necessários durante as fases tardias de 
diferenciação das CDs (Satpathy et al., 2011; Belz & Nutt, 2012). Durante 
processos infecciosos ou inflamatórios, subtipos adicionais de CDs podem ser 
gerados por monócitos e apresentar distintas funções (Cheong et al., 2010). 
Na presença de fatores de crescimento, tais como GM-CSF (fator 
estimulador de colônia para granulócitos e monócitos) e interleucina 4 (IL-4), as 
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células precursoras mielóides (CD11c+) desenvolvem funcionalmente e 
fenotipicamente características de CDs imaturas. As CDs encontradas em tecidos 
não-linfóides podem ser divididas em duas populações: células de Langerhans, 
que residem dentro do epitélio e as CDs intersticiais, presentes na derme e no 
interstício de órgãos parenquimatosos (Holíková et al., 2002). 
Na ausência de sinais inflamatórios ou infecções, as CD possuem um 
fenótipo caracterizado pela baixa expressão de moléculas do complexo de 
histocompatibilidade principal de classe II (MHC II) e das moléculas co-
estimulatórias como CD80, CD86 e CD40. Após recebimento dos sinais 
antigênicos fornecidos por lipopolissacarídeo bacteriano (LPS), DNA bacteriano, 
RNA dupla fita ou citocinas inflamatórias (IL-1, TNF-α), um irreversível processo 
de maturação é iniciado, incluindo perda da atividade endocítica, migração via 
vasos linfáticos para linfonodos e uma melhoramento na capacidade de 
estimulação das células T (Steinman et al., 1997, Guermonprez et al., 2002). 
Durante o processo de maturação, a expressão do receptor de quimiocina 
CCR6 diminui e a expressão do receptor CCR7 aumenta. A quimiocina MIP-3β, 
ligando-se ao CCR7, guia a migração das CDs maturas para os linfonodos e sua 
fixação nas áreas de células T (Dieu et al., 1998). Dessa forma, o processo de 
maturação das células dendríticas integra-se ao processo de migração das 
mesmas em direção às áreas T dos linfonodos, fazendo com que a probabilidade 
do encontro com um linfócito T antígeno-específico aumente. Nos tecidos 
linfóides, as CDs podem estar concentradas na zona de células T, sendo 
denominadas de CDs interdigitantes ou localizadas na zona de células B, 
denominadas de CDs foliculares (Noble et al., 1996).  Linfócitos B e T são os 
principais mediadores da atividade imunológica, sendo esta, em grande parte, 
dependente da interação com CDs (Banchereau & Steinman, 1998; Lanzavecchia, 
2001).  
Os receptores de reconhecimento de padrões (RRP) expressos pelas CDs 
incluem os receptores do tipo Toll (TLR), C-type lectins e o CD1a, os quais 
reconhecem características moleculares específicas expressas em patógenos 
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(Chen et al., 2006). Além disso, esses receptores também estão envolvidos no 
reconhecimento de antígenos relacionados à doenças autoimunes (TLR7). Assim, 
essas células não só são cruciais na indução da imunidade, mas também têm um 
papel fundamental na indução de tolerância imunológica central e periférica 
(Colonna, 2006). 
Além de interagir com as células T, as CDs também interagem diretamente 
com células B (Dubois et al., 1997). As CDs estimulam a diferenciação de células 
B naïve, mediada por IL-12 e regulam a imunidade inata, interagindo com células 
NK e mediando indiretamente a liberação de interferon alfa (IFN-α) (Banchereau et 
al., 2001). Uma vez que o processo de apresentação antigênica é alcançado, as 
CDs sofrem apoptose via Fas/FasL nos tecidos linfóides secundários. 
A infecção do organismo pelo vírus da imunodeficiência humana (HIV) é 
caracterizada pela seletiva depleção de linfócitos T CD4+, sugerindo um tropismo 
específico e efeito citopático desse vírus para subclasse de células T. Além dos 
linfócitos T, outras células como as pertencentes à família das CDs têm sido 
relatadas na literatura como possíveis alvos da infecção pelo HIV (Chou et al., 
2000).  As CDs estão envolvidas na disseminação do HIV, pois a maioria das CDs 
expressam os principais receptores utilizados pelo HIV como CD4, CCR5 e 
CXCR4 (Smed-Sorensen et al., 2005; Hladik et al., 2007). O vírus pode ser 
transportado e replicar nas CDs imaturas, enquanto as CDs maturas 
eficientemente transmitem a infecção para as células T CD4+ (Frankel et al., 
1996). A doença provocada pelo HIV promove uma redução do número de CDs e 
diminui a capacidade das CDs estimularem as células T. Este declínio na 
capacidade estimulatória é provavelmente o resultado da perda de moléculas 
imunologicamente importantes para as CDs. Limitadas no combate contra a 
infecção pelo HIV, as CDs acabam favorecendo a transmissão do HIV para as 
células T e disseminando a doença para vários outros sítios anatômicos (Hewson 
et al., 1999; Pope, 2000).  
 Linfonodos, tonsilas e baço de pacientes infectados pelo HIV-1 apresentam 
CDs que exibem menor expressão de moléculas co-estimulatórias do que 
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normalmente encontradas em tecidos linfóides de pacientes não infectados (Lore 
et al., 2002; Dillon et al., 2008). Linfonodos contaminados pelo HIV apresentam 
alto índice de apoptose de CDs que pode ser demonstrado pelos elevados níveis 
na expressão de caspase-3 ativada (Wijewardana et al., 2010).  
Além do HIV e devido a localização dos subgrupos de CDs na epiderme e 
derme/lâmina própria, as CDs são verdadeiros alvos de vários outros patógenos 
virais como citomegalovírus humano (CMV), o vírus do sarampo e o vírus herpes 
simples tipo 1 e 2 (HSV-1 e -2) (Halary et al., 2002; Burleigh et al., 2006; de Witte 
et al., 2007).  
Siegel et al. (1992) consideraram as infecções por HSV-1 e HSV-2 
extremamente comuns em pacientes infectados pelo HIV. Em muitos casos, o 
HSV envolve a reativação do vírus latente. A frequência da recorrência do HSV-1 
e HSV-2 depende principalmente do sítio afetado, ou seja, em regiões orofaciais o 
HSV-1 reativa mais comumente que o HSV-2, enquanto em regiões sacrais o 
HSV-2 é mais reativo (Lafferty et al., 1987). O HSV-2 reativa de três a cinco vezes 
mais em pacientes com AIDS do que indivíduos não acometidos pela doença 
(Augenbraun et al., 1995).  
O HSV-1 tem desenvolvido vários mecanismos para evadir a ação 
imunológica das CDs. Dependendo da carga viral, as CDs são maciçamente 
infectadas pelo HSV resultando em apoptose (Rad et al., 2003). Além disso, a 
infecção pelo HSV-1 afeta a função das CDs pela interferência no processo de 
maturação, incluindo desregulação de moléculas estimulatórias como CD1a,  
CD83 e MHC I (Raftery et al., 2006; Kummer et al., 2007). O HSV-1 também 
diminui a produção de interleucina 12 (IL-12), diminuindo a capacidade 
estimulatória das CDs (Theodoridis et al., 2007). 
Dessa forma, o presente estudo tentou promover um melhor entendimento 
da influência do HIV na população de CDs em linfonodos e tonsilas palatinas e o 
impacto da infecção combinada HIV-HSV na população de CDs intersticiais em 
tecidos linguais. 
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CAPÍTULO 1 
  
Artigo submetido para possível publicação no periódico Histopathology.  
  
Reduced number of CD1a+ and CD83+ interstitial dendritic cells in herpetic 
lesions (HSV-1+) of the tongue in patients with advanced-stage AIDS. 
 
Rogério O Gondak,1 Thais Mauad,2 Oslei P Almeida1 & Pablo A Vargas1 
 
1Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, 
Piracicaba, Brazil 
2Department of Pathology, Sao Paulo University Medical School, São Paulo, 
Brazil. 
 
Abbreviations: Ab, antibody; Ag, antigen; AIDS, acquired immunodeficiency 
syndrome; DC, dendritic cell; H&E, haematoxylin and eosin; HAART, highly active 
antiretroviral therapy; HIV, human immunodeficiency virus; HSV, herpes simplex 
virus; iDC, interstitial dendritic cell; IL, interleukin; LC, Langerhans cell; MHC, major 
histocompatibility complex; pDC, plasmacytoid dendritic cell; TNF, tumor necrosis 
factor. 
 
ABSTRACT 
 
Aims: The purpose of this study was to quantify and compare the density of 
interstitial dendritic cells (iDCs) in the tongue mucosa of AIDS patients with and 
without herpes simplex and normal tongue of non-AIDS patients using autopsy 
material. 
 Methods and results: CD83, CD1a and HSV-1 antibodies were used to 
identify mature DCs, immature DCs and herpes simplex type 1, respectively, by 
immunohistochemistry in tongue tissue from 20 AIDS patients (10 with lingual 
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herpes and 10 with normal tongue) and 10 from HIV-negative control patients. 
Quantification was performed by means of conventional morphometry and the 
results were expressed as positive cells per area of lamina propria. AIDS patients 
presented a lower density of CD83+cells (P < 0.001) and CD1a+cells (P < 0.001) 
compared to the non-AIDS control group. However, no differences in the number of 
iDCs was found in tongues from AIDS patients with or without herpes infection. 
 Conclusions: Individuals with advanced AIDS present a decreased 
population of iDCs independent of the presence of concomitant infection by HSV. 
 
Keywords:  AIDS, dendritic cells, herpes simplex, tongue, CD1a antigen; CD83 
antigen. 
 
INTRODUCTION 
 
Dendritic cells (DCs) are a heterogeneous population of cells with high 
phagocytic activity as immature cells and high cytokine-producing capacity as 
mature cells.1,2 DCs are highly migratory cells that move from tissues to the T cell 
and B cell zones of lymphoid organs via afferent lymphatics and endothelial 
venules, and regulate T cell responses in the steady state and during infections.3,4 
The two major DC populations in oral tissues are: Langerhans cells (LCs) located 
in the mucosal epithelium and interstitial dendritic cells (iDCs), the equivalent of 
dermal DCs in the skin that are located in the subepithelium.5-7 
Viruses manipulate the function of DCs to enhance their entry, spread, 
survival and transmission. Different viruses such as herpes viruses and human 
immunodeficiency virus (HIV) may have opposite effects on DC function, 
determined by the need for transfer to a primary target cell, replication within DCs 
or various immunoevasive mechanisms.8 
We have previously reported the depletion of LCs in the intraepithelial areas 
in tongues from AIDS patients with different opportunistic infections.9 In this work, 
we describe the effects of HIV and HSV infections on iDCs in the tongue.  
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MATERIALS AND METHODS 
 
The Ethics Committee of the Medical School of São Paulo University 
approved this study and the use of autopsy material. 
 
Patient population 
The tongues of 20 autopsied patients with advanced AIDS were collected 
from 1997 to 2009 in the Department of Pathology, São Paulo University, Medical 
School. Ten patients had a diagnosis of lingual herpes confirmed histologically and 
10 had no microscopic alterations on the tongue. Moreover, normal tongues from 
10 patients who died of other diseases not associated with AIDS were used as a 
control.  Records of clinical data and autopsies of a part of this population have 
been previously described.9  
 
Tissue processing 
 The tongues were fixed in 10% formalin for 24 hours and 6 transverse 
sections from each tongue were obtained. All fragments were embedded in paraffin 
and 3-µm thick histological sections were submitted to H&E staining and 
immunohistochemistry for CD1a, CD83 and HSV-1. 
 
Immunohistochemistry 
Polyclonal HSV-1 antibody (Dako, 1:7000) was used for the detection of 
HSV infection. Monoclonal antibodies against CD1a (010, Dako, 1:80) and CD83 
(1H4b, Novocastra, 1:20) were used for the identification of iDCs in the lamina 
propria of the tongues. The final antibody was used for staining of mature iDCs.  
Antigen retrieval with citrate was performed for all antibodies. The slides 
were incubated with secondary antibodies conjugated with horseradish peroxidase 
(LSAB + System-HRP, Mouse / Rabbit, Dako) for 30 minutes at 37°C. Afterward, 
the slides were incubated with Streptavidin-HRP (Dako) for another 30 minutes 
and developed with chromogenic substrate (3,3 diaminobenzidine-DAB, Sigma). 
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The slides were then counterstained with Harris hematoxylin. Negative controls 
were performed for each reaction omitting the primary antibodies. 
 
Microscopic analysis 
Quantification of iDCs was performed using a light microscope (Carl Zeiss, 
Berlin, Germany) with a 40x objective and 8x reticulated square (Reichert, Vienna, 
Austria) having a length of 150 μm and an area of 22,500 μm2. Cells that were 
positive for CD1a and CD83 in the lamina propria of all tongues were counted 
including the lesional areas (group with lingual herpes) and non-lesional areas 
(normal tongues). For each case, 7 sequential fields were quantified, totaling an 
area of 1 mm2 of analysed tissue in each region.9 Results were expressed as 
positive cells per mm2 of lamina propria. 
 
Statistical analysis 
 Values are expressed as mean ± SD or median (interquartile ranges). 
Comparison among groups was performed by ANOVA and Kruskal-Wallis test 
followed by the Bonferroni post-hoc test. A P value of < 0.05 was considered as 
statistically significant. The statistical software SPSS version 17.0 was used for the 
analyses. 
 
RESULTS 
 
Control group 
The control group consisted of 6 male and 4 female patients. The mean age 
was 55.1 ± 4 years (ranging from 49 to 60 years). The main autopsy findings 
included acute myocardial infarct, congestive heart failure, hypovolemic shock, 
pulmonary thromboembolism and subarachnoid haemorrhage. 
 
AIDS groups 
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The AIDS groups consisted of 14 males and 6 females. The mean age was 
37 ± 11 years (ranging from 25 to 69 years). The mean CD4+ T lymphocyte blood 
counts were 98 ± 139 cells/µL. The mean CD4+/CD8+ T-cell ratio was 0.25 ± 0.47. 
There were no differences in the CD4+ T lymphocytes blood counts and in the 
CD4+/CD8+ T-cell ratio between the two groups of AIDS patients (P = 0.721). The 
main autopsy findings in AIDS patients were: cryptococcal meningitis, pneumonia, 
pneumocystosis, pulmonary thromboembolism, septic shock, tuberculosis and 
meningitis. 
 
Microscopic findings 
The histopathological findings in these samples have been published 
previously.10  
Microscopically, acantholytic and multinucleated keratinocytes in the 
herpetic lesions of the tongue showed the typical molding of the nuclei as well as 
margination of the chromatin (Figure 1A). The diagnosis of HSV-1 was confirmed 
by immunohistochemistry (Figure 1B). 
CD1a and CD83 staining showed positive cells with limited dendritic 
extensions in the lamina propria, mostly localized in the subepithelial region and 
near blood vessels. The density of CD1a+ cells was less than that of CD83+ cells. 
 
Interstitial dendritic cell quantification 
Patients with AIDS presented significantly lower densities of CD1a+ cells 
(12.53 ± 11.99 /mm2, P < 0.001) and CD83+ cells (14.76 ± 12.07/mm2, P < 0.001) 
than the controls, which presented values of 60.47 ± 40.56/mm2 and 77.61 ± 29.74 
/mm2, respectively, for CD1a and CD83 (Figure 2). On the other hand, the 
densities of iDCs were similar in the 2 groups of AIDS patients with or without 
herpes simplex infection of the tongue (CD1a, P = 0.856 and CD83, P = 0.816). 
The data are shown in Figure 3.   
There were no correlations between CD1a+, CD83+ cells and CD4+ T-cells 
counts or CD4+/CD8+ T-cell count ratios (data not shown). 
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DISCUSSION  
  
 In this work, we showed that the density of CD1a+ and CD83+ iDCs in the 
lamina propria of tongues from AIDS patients was lower than in non-AIDS patients. 
Interestingly, the density of iDCs was similar in the tongues of AIDS patients with 
or without lingual herpes infection (HSV-1). Similar findings were also observed in 
a previous study from our group comparing the population of LCs in tongues of 
AIDS patients with oral opportunistic infections.9 To our knowledge, this is the first 
study of iDCs in AIDS patients with lingual herpes using autopsy material. 
As sentinels of the immune system, DCs have important regulatory 
functions. Due to their specific location, DCs are a target for invading pathogens 
such as HIV-1 and HSV.11,12 HSV-1 infection strongly affects DC function by 
interfering with DC maturation, including downregulation of costimulatory 
molecules as well as CD83 and CD1.13,14 
According to Bosnjak et al.15 HSV infections of the skin or mucosa are 
determined by complex interactions between virus immunoevasive mechanisms 
and the host immune system. HSV induces only partial impairment of DC function, 
and the infection is probably controlled by responses generated from uninfected 
DCs presenting infected cell debris.16,17 Depending on the viral load, infected DCs 
are functionally compromised and may rapidly die, which would further decrease 
their contribution to overall T cell priming.18,19  
A series of genetic lesions, idiopathic conditions and co-infections are 
associated with deficient DC responses to HSV and with severe primary HSV 
infections.20,21 HIV co-infection is associated with low plasmacytoid dendritic cell 
(pDC) numbers and poor pDC responses to HSV.22 Decreased numbers of 
circulating pDCs and HSV responsiveness were seen in persons with HSV-1 
retinitis.23 Moreover, HSV has developed several immune evasion mechanisms, 
including inhibition of complement and Ab binding, DC function, and MHC class I-
mediated Ag presentation on infected cells.24 DC maturation is required for optimal 
activation of naive T cells and entails a set of phenotypic changes that can be 
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induced directly by the pathogen via pattern recognition receptors or indirectly 
through danger signals, such as IL-1β or TNF-α, that are secreted by the 
surrounding cells.25  
In the present study, we showed intense depletion of iDCs in groups 
independent of HSV infection. These findings suggest a greater potential role of 
HIV in the marked decline of the iDCs in the tongues of patients. Furthermore, 
larger numbers of CD83+ cells than CD1a+ cells were noted in all groups, in 
contrast to our previous study.9 Because there are DCs in a more advanced stage 
of maturation in the lamina propria than in the oral epithelium, an increased 
expression of CD83+ cells is expected.26,27  
Patients with HIV infection alone or HIV-HSV-1 coinfection showed no 
difference between CD4+/CD8+ cell counts (P = 0.58). In a longitudinal study 
involving individuals with HIV with different rates of disease progression, Fontaine 
et al.28 showed that myeloid DC levels were reduced in the blood of rapid and 
classic progressors, beginning in the acute phase of infection and persisting 
throughout the course of disease, despite successful therapy. This correlated with 
increased serum levels of DC-tropic chemokines, suggesting drainage to 
peripheral sites.29  
A limitation of the current study was the age difference between the groups. 
Although there was no statistical difference among the ages of the AIDS patients 
(P = 0.39), there were significant differences between AIDS and non-AIDS patients 
(P < 0.001). Nevertheless some studies suggest that aging leads to a decline in 
immune cells, including dendritic cells.30,31 In addition, it will be important to 
perform new studies that include HIV patients on highly active antiretroviral therapy 
(HAART) to verify the interference of this treatment on the population of DCs. 
Thus, we conclude that advanced-stage AIDS patients suffer a profound 
depletion of iDCs in the tongue mucosa regardless of herpes infection. Further 
advances in this area are necessary for a better understanding of antiviral 
mechanisms. 
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FIGURES AND LEGENDS 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A, Epithelial cells infected with HSV showing typical molding of the nuclei 
and intense subepithelial inflammatory infiltrate (H&E, x 200). 
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Figure 1. B, Immunohistochemical detection of HSV-1 in epithelial cells (high 
magnification, 400 x).  
 
Figure 2. Interstitial dendritic cells in the lamina propria of the tongue. A, CD1a+ 
cells (AIDS with herpes); B, CD1a+ cells (AIDS no lesions); C, CD1a+ cells 
(control group); D, CD83+ cells (AIDS with herpes); E, CD83+ cells (AIDS no 
lesions); F, CD83+ cells (control group). High magnification, 200 x.   
1
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ABSTRACT 
Aims: The purpose of this study was to quantify and compare the density of 
dendritic cells (DCs) in cervical lymph nodes (LNs) and palatine tonsils (PTs) of 
AIDS and non-AIDS patients. 
Methods: Factor XIIIa, CD1a and CD83 antibodies were used to identify 
conventional DCs by immunohistochemistry in LNs and PTs of 32 AIDS patients 
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and 21 HIV-negative control patients. Quantification was performed by the Positive 
Pixel Count analytical method.  
Results: AIDS patients presented a lower density of Factor XIIIa+ cells (P < 
0.001), CD1a+cells (P < 0.05) and CD83+ cells (P < 0.001) in cervical LNs and 
PTs compared to the non-AIDS control group. 
Conclusion: Overall depletion of DCs in lymphoid tissues of AIDS patients 
may be predictive of the immune system’s loss of disease control. 
 
Keywords: AIDS; dendritic cells; lymph node; palatine tonsil; 
immunohistochemistry. 
 
INTRODUCTION 
 
Dendritic cells (DCs) are a heterogeneous population of cells with high 
phagocytic activity as immature cells and high cytokine-producing capacity as 
mature cells that work to maintain a balance between tolerance and protective 
immunity.1,2 DCs are the most potent professional antigen-presenting cells required 
to initiate immune responses. After an antigen capture, DCs migrate to regional 
lymph nodes (LNs) via afferent lymphatics and endothelial venules regulating T cell 
responses in the steady state and during infections.3,4  
Depending on location, function and level of maturation, DCs can present 
variable phenotypes. Immature DCs express CD1a and in the steady state are 
located at the epithelial surface of the skin, the gastrointestinal, respiratory, and 
genitourinary tracts5 and in lymphoid organs.6 Factor XIIIa+ DCs are located in the 
dermis as dermal DCs, in the interstitial areas of solid organs, and admixed with 
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lymphocytes in the interfollicular area of the LNs.7 During the maturation process, 
DCs express CD83 as thymic DCs, circulating DCs, interdigitating reticulum cells 
present in the T cell zones of lymphoid organs, some germinal center cells, and 
monocyte derived DCs.8 However, CD1a, factor XIIIa and CD83+ cells have rarely 
been investigated in LNs9,10 or palatine tonsils (PTs) of AIDS patients. 
DCs are susceptible to infection by HIV in vitro and in vivo.11,12 HIV causes a 
marked depletion of DCs in HIV-1 positive patients, and impaired cytokine 
secretion and ability to stimulate T cells.13,14  
We have previously reported the depletion of immature DCs in the 
intraepithelial areas of tongues from AIDS patients with different opportunistic 
infections.15 In this work, we describe the effects of HIV infection on DCs in cervical 
LNs and PTs. 
 
MATERIALS AND METHODS 
 
The Ethics Committee of the University of Campinas and University of São 
Paulo approved this study and the use of autopsy material according to ethical 
guidelines. 
 
Patient population 
Cervical LNs and PTs from 32 autopsied patients with AIDS were collected 
at the University of São Paulo between 1997 and 2011. In addition, 21 uninfected 
patients that had LNs and PTs dissected between 2010 and 2012 for diagnostic or 
therapeutic reasons at the University of Campinas and Instituto de Anatomia 
Patologica (Piracicaba, SP) were included in the study. Clinical charts and autopsy 
reports from all patients were reviewed and the last CD4+ and CD8+ T cell counts 
prior to the deaths of the 32 AIDS patients were obtained. 
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Tissue processing 
Cervical LNs and PTs were fixed in 10% formalin for 24 hours and 6 
transverse sections were obtained. All fragments were embedded in paraffin and 3-
µm thick histological sections were submitted to H&E staining and 
immunohistochemistry. 
 
Immunohistochemistry 
Immunoassays using monoclonal antibodies against CD1a (010, Dako, 
1:80), CD83 (1H4b, Novocastra, 1:20) and Factor XIIIa (E980.1, Novocastra, 
1:100) were carried out for the identification of DCs in the cervical LNs and PTs. 
Antigen retrieval with citrate was performed for all antibodies. The slides were 
incubated with secondary antibodies conjugated with horseradish peroxidase 
(LSAB + System-HRP, Mouse / Rabbit, Dako) for 30 minutes at 37°C. Afterward, 
the slides were incubated with Streptavidin-HRP (Dako) for another 30 minutes 
and developed with chromogenic substrate (3,3 diaminobenzidine-DAB, Sigma). 
The slides were counterstained with Harris hematoxylin. Negative controls were 
performed for each reaction, omitting the primary antibodies. 
 
Microscopic analysis  
Quantification was performed by the Positive Pixel Count Algorithm method 
using ImageScope software (Aperio, Vista, CA, USA). Positive Pixel Count is a 
multipurpose algorithm that quantifies the area and intensity of stains. Pixels were 
classified according to intensity of staining and colour. The intensity of staining was 
classified as strongly positive (red), positive (orange), weakly positive (yellow), or 
negative (blue) (Figure 1). A minimum area of 1mm2 of lymphoid tissue was 
considered and the microscopic analysis was done at full 20x magnification. The 
results were expressed in percent positive area. 
Statistical analysis 
Statistical differences between groups were estimated using a standard non-
parametric test (Mann-Whitney U-test). The results are presented as median and 
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interquartile ranges. Differences at P < 0.05 were considered as statistically 
significant. The statistical software SPSS version 17.0 was used for the analyses. 
 
RESULTS 
 
Clinical findings 
The control group consisted of lymphoid tissue from 12 male patients and 9 
females. The mean age was 38.7 ± 17.2 years (ranging from 15 to 84 years). The 
main clinical findings in control patients were: diabetes, hepatitis B, cardiovascular 
disease, asthma and obesity. 
The AIDS group consisted of 24 males and 8 females. The mean age was 
37.4 ± 10.5 years (ranging from 15 to 69 years). The mean CD4+ T lymphocyte 
blood counts were 74 ± 104 cells/µL. The mean CD4+/CD8+ T-cell ratio was 0.21 ± 
0.35. The main autopsy findings in AIDS patients were: pneumonia, 
pneumocystosis, pulmonary thromboembolism, septic shock, tuberculosis and 
meningitis. 
 
Microscopic findings 
 Microscopically, factor XIIIa, CD1a and CD83 staining showed positive cells 
with abundant cytoplasm, ill-defined borders and interdigitating processes. These 
cells were located mainly in the T cell areas of secondary lymphoid organs. In 
control individuals, we observed a higher density of all markers in cervical LNs and 
PTs (Figures 2 and 3).    
 
Dendritic cells quantification 
Patients with AIDS had a smaller percentage of DCs in cervical LNs (Factor 
XIIIa+ cells, P < 0.001; CD1a+ cells, P = 0.048; and CD83+ cells, P < 0.001) and 
PTs (Factor XIIIa+ cells, P < 0.001; CD1a+ cells, P = 0.027; and CD83+ cells, P < 
0.001) compared to the control group (Figure 4).  
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  Within the AIDS group, there was no statistically significant difference in the 
percentage of DCs between cervical lymph nodes and palatine tonsils (Factor 
XIIIa+ cells, P = 0.989; CD1a+ cells, P = 0.998; and CD83+ cells, P = 0.999). This 
finding was also observed between the two distinct anatomic regions in the control 
group (Factor XIIIa+ cells, P = 0659; CD1a+ cells, P = 0994; and CD83+ cells, P = 
0665). The data are shown in Table 1.  
  
DISCUSSION 
 
The continuous migration of DCs into secondary lymphoid organs such as 
LNs represents a fundamental element of immune surveillance and homeostasis.16 
Within LNs, DCs present antigens to cognate T cells, resulting in the induction of 
protective immunity.17,18 In this study, we showed that the density of Factor XIIIa+, 
CD1a+ and CD83+ DCs in cervical LNs and PTs from AIDS patients was less than 
in non-AIDS patients. These findings extend the results seen in a previous study 
from our group that analysed the Langerhans cells population, a subset of DCs, in 
the tongues of AIDS patients,15 demonstrating that the HIV virus promotes the 
overall depletion of DCs in lymphoid organs as well as oral tissues.  
 According to Donaghy et al.12, the decline in circulating DCs correlates with 
an increase in HIV-1 viral load and this depletion correlates with disease 
progression. HIV-1-exposed DCs retain their ability to mature phenotypically, which 
is crucial to their transition into potent antigen-presenting cells.19 Moreover, the 
loss of DCs from blood could be a consequence of the increased migration of DCs 
to lymphoid organs or insufficient repopulation of blood DCs.20  
DC biology suggests that half of the DCs within LNs enter from the 
bloodstream and the other half are believed to arise from lymph-migrating tissue 
DCs.21 Within interfollicular areas of the lymph node cortex, the fibroblastic reticular 
cell network extends close to the subcapsular sinus floor and serves as a port of 
entry for cells arriving with the afferent lymph.22,23 Activated DCs arrive largely via 
afferent lymph and remain confined to the subcapsular sinus of the afferent side of 
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the lymph node, migrating towards the deeper paracortical T cell zone through 
interfollicular areas of the cortex.16,24,25 Only a minority of lymph node DCs in the 
steady state arise from DCs residing in upstream nonlymphoid organs. Instead, 
DCs that migrate through lymphatics from upstream tissues contribute substantially 
to the pool of lymph node DCs, mainly during inflammatory states.26  
Immature and mature DCs were initially thought to occur in specific 
anatomic locations: immature DCs capture Ags in peripheral tissues whereas 
mature DCs present those Ags on their MHC molecules in the T cells areas of the 
draining lymphoid organs.27 However, it has been shown that lymphoid organs 
such as tonsil, lymph node, thymus and spleen also contain large cohorts of 
immature DCs.6,28 These DCs can either respond to infections reaching those 
organs and mature in situ or play a role in the maintenance of immunological 
peripheral tolerance.29,30 This condition was observed in our study as the high 
density of factor XIIIa+ cells (immature DCs) in lymphoid tissues compared to 
CD83+ cells (mature cells). Moreover, factor XIIIa antibody can also be detected in 
a number of monocyte-derived macrophage lineages, including macrophages, 
histiocytic and dendritic reticulum cells, in LNs.31,32 On the other hand, the density 
of CD1a+ cells was less than that shown by the other antibodies, because mature 
DCs, which are common in secondary lymphoid organs, express low levels of 
CD1a.33 
After HIV crosses the mucosa or skin, it reaches the lymphoid tissue and 
permanent infection is established. The interaction between DCs and T-cells in 
lymphoid tissue is critical for the generation of immune responses. DCs are 
suggested to play a crucial role in the early events of HIV transmission by 
transporting the virus from the peripheral tissues to the lymphoid system and 
creating a perfect microenvironment for HIV-1 replication.34,35 Some studies have 
suggested that DCs maintain their ability to stimulate T-cells after HIV 
exposure.36,37 
During HIV infection, the majority of DCs can most likely respond to 
stimulation and present antigen to T cells, although the quality of the response may 
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be altered and exhibit a lower expression of molecules than what is normally found 
in lymphoid tissues.20,38 
  Nevertheless, factor XIIIa+, CD1a+ and CD83+ cells were located mostly in 
the cortical areas of LNs, in agreement with other authors39,40 who reported that 
DCs were located in the T-cell-dependent areas of lymphoid tissues, in the skin, 
lungs and gut where antigens enter the body. The main DCs located in the T zone 
are designated interdigitating DCs, representing a population of mature DCs with 
high potential to stimulate lymphocytes and with high level expression of MHC 
class II and cytokines including IL-6, IL-10 and IL-13.1,41,42    
 Several investigations have demonstrated that DCs are also involved in 
regulating T-cell-mediated humeral immune responses, indicating that naive B cells 
interact with DCs in human tonsils.41,43 Interdigitating dendritic cells (IDCs) interact 
with the large number of resting naive B cells directly in the T-cell area of the lymph 
node and are positive for mature-DC markers such as CD80, CD83 and CD86.44,45  
 DCs may influence B cell responses against HIV through contact or 
production of B cell growth factors such as B lymphocyte stimulator (BLyS/BAFF) 
that modulate the outcome of CD4 T cell HIV effectors.46 Some longitudinal studies 
involving HIV patients with different rates of disease progression have shown that 
DC levels were reduced in the blood beginning in the acute phase of infection and 
persisting throughout the course of disease despite successful therapy.47 This 
condition has been correlated with increased serum levels of DC-tropic 
chemokines and drainage to peripheral sites, and has also been associated with 
inflammatory conditions.48,49 
 The present study had some limitations. We studied the population of DCs 
in lymphoid tissues of patients with AIDS and severe immunosuppression because 
most of the patients died before highly active antiretroviral therapy (HAART) 
initiation. Hence, it would be interesting to study the distribution of DCs in LNs of 
HIV positive patients in different stages of disease or on HAART. A better 
understanding of the tissue distribution of DCs in HIV-infected patients may 
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contribute to the development of new therapeutic strategies and to inducing 
favourable adaptive anti-HIV immunity.38 
In conclusion, advanced-stage AIDS patients have a profound depletion of 
DCs in cervical LNs and PTs that may be predictive of the immune system’s loss of 
disease control. Advances regarding the role of DCs in HIV-1 infection will be 
important for the establishment of antiviral mechanisms and/or control of viral 
spread. 
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TABLE 
 
Table 1. Cell density in cervical lymph nodes and palatine tonsils. 
Cell types 
Cell density (%) in 
Cervical lymph node Palatine tonsil 
AIDS patients Control group AIDS patients Control group 
Factor XIIIa 
 
7,52 ± 3,83 
 
 
44,53 ± 20,18
a
 
 
 
5,76 ± 2,24 
 
38,03 ± 13,70
a
 
CD1a 
 
2,05 ± 0,98 
 
 
11,83 ± 9,25
b
 
 
 
1,62 ± 0,77 
 
11,28 ± 12,13
b
 
CD83 
 
2,31 ± 1,44 
 
 
15,48 ± 9,66
a
 
 
 
1,94 ± 1,21 
 
16,47 ± 11,28
a
 
  a 
P < 0.001 in relation to AIDS group. 
b
 P < 0.05 in relation to AIDS group. 
 
32 
 
FIGURES AND LEGENDS 
 
Figure 1. Immunostaining evaluation method using Image Scope software. A. 
Factor XIIIa+ cells in a cervical lymph node from a control patient. B. Delimitation of 
the area to be analyzed in mm2. C. Positive Pixel Count function measuring the 
intensity of staining according to specific colour (blue = negative, yellow = weakly 
positive, orange = medium positive, red = strongly positive).  
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Figure 2. A,B,C; Immunohistochemical expression of factor XIIIa+, CD1a+ and 
CD83+ cells in cervical lymph nodes in the control group, respectively. High 
concentrations of positive cells in the paracortical T cell zone through interfollicular 
areas of the cortex D,E,F; Factor XIIIa+, CD1a+ and CD83+ cells in the cervical 
lymph nodes in the AIDS group showing profound depletion of dendritic cells (high 
magnification, 200 x).  
 
Figure  3. Representative immunohistochemical stainings of palatine tonsils. A, B, 
C. Factor XIIIa+, CD1a+ and CD83+ cells, respectively, in the control group. D,E,F  
Depletion of factor XIIIa+, CD1a+ and CD83+ cells, respectively, in the AIDS group 
(high magnification, 200 x).    
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CONCLUSÃO 
 
 Houve uma intensa redução na população de CDs intersticiais na língua 
de pacientes com AIDS; 
 Pacientes com AIDS e portadores de infecção herpética lingual não 
apresentaram diferenças significativas na quantificação de CDs intersticiais 
quando comparados com pacientes com AIDS e sem lesões linguais; 
 O HIV promoveu uma depleção significativa de CDs tanto em linfonodos 
cervicais quanto em tonsilas palatinas. 
 
 
 
   
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
REFERÊNCIAS*  
 
1. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu 
Rev Immunol. 2012;30:1-22. 
2. Hart DNJ. Dendritic cells: unique leukocyte populations which control the 
primary immune response. J Amer Soc Hematol. 1997;90:3245-87. 
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 
1998;392:245-52. 
4. Shortman K, Naik SH. Steady-state and inflammatory dendritic cell deve-
lopment. Nat Rev Immunol. 2007;7:19-30. 
5. Mclellan AD, Kämpgen E. Functions of myeloid and lymphoid dendritic cells. 
Immunol Let. 2000;72:101-5. 
6. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv 
Exp Med Biol. 1997;417:1–6. 
7. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol 
Rev. 2010;234:45-54. 
8. Satpathy AT, Murphy KM, KC W. Transcription factor networks in dendritic cell 
development. Semin Immunol. 2011;23:388-97. 
9. Belz GT, Nutt SL. Transcriptional programming of the dendritic cell network. Nat 
Rev Immunol. 2012;12:101-13. 
10. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates 
monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 
2010;143:416-29.  
11. Holíková JPZ, Smetana Jr K, Riedel F, et al. The role of dendritic cells in the 
pharynx. Eur Arch Otorhinolaryngol. 2003;260:266–72.  
12. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. 
Adv Exp Med Biol. 1997;417:1–6. 
___________________ 
* De acordo com a norma da UNICAMP/FOP, baseada na norma do International Committee of Medical 
Journal Editors – Grupo Vancouver. Abreviatura dos periódicos em conformidade com o Medline. 
37 
 
13. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell 
stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-67. 
14. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature 
dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp 
Med. 1998;188:373-86. 
15. Noble B, Frankel S, Gorfien J, et al. Microanatomical distribution of dendritic 
cells in normal tonsils. Acta Otolaryngol Suppl. 1996;523:94–7. 
16. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. 
Cell. 2001;106:263-6.  
17. Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host-pathogen 
interface. Nat Immunol. 2006;7:117-20. 
18. Chen CH, Floyd H, Olson NE et al. Dendritic-cell-associated C-type lectin 2 
(DCAL-2) alters dendritic-cell maturation and cytokine production. Blood. 
2006;107:1459-67. 
19. Dubois B, Vanbervliet B, Fayette J, et al. Dendritic cells enhance growth and 
differentiation of CD40-activated B lymphocytes. J Exp Med. 1997;185: 941–51. 
18. Banchereau J, Schuler-Thurner B, Palucka K, et al. Dendritic cells as vectors 
for therapy. Cell. 2001;106:271–4. 
19. Chou LL, Epstein J, Cassol AS, et al. Oral mucosal Langerhans cells as target 
effector and vector in HIV infection. J Oral Pathol Med. 2000;29:394-402.   
20. Smed-Sorensen A, Lore K, Vasudevan J, et al. Differential susceptibility to 
human immunodeficiency virus type 1 infection of myeloid and plasmacytoid 
dendritic cells. J Virol. 2005;79:8861–9. 
21. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing 
vaginal entry and infection by human immunodeficiency virus type-1. Immunity 
2007;26:257–270. 
22. Frankel SS, Wenig BM, Burke AP, et al. Replication of HIV-1 in dendritic cell-
derived syncytia at the mucosal surface of the adenoid. Science. 1996;272:115–7. 
23. Hewson T, Loone N, Moore M, et al. Interactions of HIV-1 with antigen 
presenting cells. Immunol Cell Biol. 1999;77:289–303. 
38 
 
24. Pope M. Mechanisms of mucosal immunity: How does the dendritic cell fit in? 
AIDS Patient Care STDS. 2000;14:207–10. 
25. Lore K, Sonnerborg A, Broström C, et al. Accumulation of DC-SIGN+CD40+ 
dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during 
acute HIV-1 infection. AIDS. 2002;16:683–92. 
26. Dillon SM, Robertson KB, Pan SC, et al. Plasmacytoid and myeloid dendritic 
cells with a partial activation phenotype accumulate in lymphoid tissue during 
asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2008; 48:1–
12. 
27. Wijewardana V, Soloff AC, Liu X, et al. Early myeloid dendritic cell 
dysregulation is predictive of disease progression in simian immunodeficiency virus 
infection. PLoS Pathog. 2010;6:e1001235. 
28. Halary F, Amara A, Lortat-Jacob H, et al. Human cytomegalovirus binding to 
DC-SIGN is required for dendritic cell infection and target cell transinfection. 
Immunity. 2002;17:653–64. 
29. Burleigh L, Lozach PY, Schiffer C, et al. Infection of dendritic cells (DCs), not 
DC-SIGN-mediated internalization of human immunodeficiency virus, is required 
for long term transfer of virus to T cells. J Virol. 2006;80:2949–57. 
30. de Witte L, Bobardt M, Chatterji U, et al. Syndecan-3 is a dendritic cell specific 
attachment receptor for HIV-1. Proc Natl Acad Sci USA. 2007;104:19464–9. 
31. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes 
simplex infections. The population-based AIDS in multiethnic neighborhoods study. 
JAMA. 1992;268:1702-8. 
32. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital 
herpes simplex virus action: influence of site of infection and viral type. N Engl J 
Med. 1987;316:1444-9. 
33. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of 
herpes-simplex virus type-2 in HIV-positive women. Ann Intern Med. 1995;123: 
845-7. 
39 
 
34. Rad AN, Pollara G, Sohaib SM, et al. The differential influence of allogeneic 
tumor cell death via DNA damage on dendritic cell maturation and antigen 
presentation. Cancer Res. 2003;63:5143-50. 
35. Raftery MJ, Winau F, Kaufmann SH, et al. CD1 antigen presentation by human 
dendritic cells as a target for herpes simplex virus immune evasion. J Immunol. 
2006;177:6207–14. 
36. Kummer M, Turza NM, Muhl-Zurbes P, et al. Herpes simplex virus type 1 
induces CD83 degradation in mature dendritic cells with immediate-early kinetics 
via the cellular proteasome. J Virol. 2007;81:6326–38. 
37. Theodoridis AA, Prechtel AT, Turza NM, et al. Infection of human dendritic cells 
with herpes simplex virus type 1 dramatically diminishes the mRNA levels of the 
prostaglandin E2 receptors EP2 and EP4. Immunobiology. 2007;212:827–38. 
4
0
 
 
A
N
E
X
O
 
A
n
e
x
o
 1
 –
 C
e
rtific
a
d
o
 d
o
 C
o
m
itê
 d
e
 É
tic
a
 e
m
 P
e
s
q
u
is
a
 d
a
 F
a
c
u
ld
a
d
e
 
d
e
 O
d
o
n
to
lo
g
ia
 d
e
 P
ira
c
ic
a
b
a
 (F
O
P
-U
n
ic
a
m
p
) 
   
41 
 
Anexo 2 – Certificado da Comissão de Ética para Análise de Projetos 
de Pesquisa do Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo (CAPPesq – FMUSP)  
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Anexo 3 – Declaração de alteração de Pesquisador Executante no 
Hospital das Clínicas da Faculdade de Medicina da Universidade de 
São Paulo (HC-FMUSP) 
 
 
 
 
 
 
